Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of Drugs in Dermatology : JDD|August 6, 2010
Scalp psoriasis: an overview of the disease and available therapiesJeffrey CrowleyJournal of Drugs in Dermatology : JDD|October 17, 2006
Successful treatment of hand and foot psoriasis with efalizumab therapyScott Fretzin, Jeffrey Crowley, Loretta Jones, et al.Issue Brief (Commonwealth Fund)|March 28, 2006
Using clinical evidence to manage pharmacy benefits: experiences of six statesDavid Bergman, Jack Hoadley, Neva Kaye, et al.The Journal of Dermatological Treatment|July 15, 2022
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal respondersBruce Strober, April Armstrong, Simone Rubant, et al.Journal of the American Academy of Dermatology|November 10, 2015
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)Phoebe Rich, Melinda Gooderham, Hervé Bachelez, et al.Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods StudySuzanne Murray, Jeffrey Crowley, Melinda J Gooderham, et al.Dermatology and Therapy|February 9, 2024
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)Melinda Gooderham, Ronald Vender, Jeffrey Crowley, et al.The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.Annals of the Rheumatic Diseases|January 22, 2016
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, et al.Journal of the American Academy of Dermatology|April 19, 2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)Jeffrey Crowley, Diamant Thaçi, Pascal Joly, et al.Pageof 2